These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 39110114)

  • 1. Rate of dupilumab use and symptom severity of patients with chronic rhinosinusitis with nasal polyposis after Draf 3 frontal sinusotomy.
    Ji K; Kellerman H; Mace JC; Smith TL; Detwiller KY; Joshi SR; Geltzeiler M
    Int Forum Allergy Rhinol; 2024 Aug; ():. PubMed ID: 39110114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Equivalence in outcomes between Draf 2B vs Draf 3 frontal sinusotomy for refractory chronic frontal rhinosinusitis.
    Patel VS; Choby G; Shih LC; Patel ZM; Nayak JV; Hwang PH
    Int Forum Allergy Rhinol; 2018 Jan; 8(1):25-31. PubMed ID: 29131540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing the timing of biologic and surgical therapy for patients with refractory chronic rhinosinusitis with nasal polyposis (CRSwNP).
    Garvey E; Naimi B; Duffy A; Hannikainen P; Kahn C; Farquhar D; Rosen M; Rabinowitz M; Toskala E; Nyquist G
    Int Forum Allergy Rhinol; 2024 Mar; 14(3):651-659. PubMed ID: 37506043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative analysis of endoscopic sinus surgery versus biologics for treatment of chronic rhinosinusitis with nasal polyposis.
    Miglani A; Soler ZM; Smith TL; Mace JC; Schlosser RJ
    Int Forum Allergy Rhinol; 2023 Feb; 13(2):116-128. PubMed ID: 35980852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of modified endoscopic Lothrop in aspirin-exacerbated respiratory disease with nasal polyposis.
    Morrissey DK; Bassiouni A; Psaltis AJ; Naidoo Y; Wormald PJ
    Int Forum Allergy Rhinol; 2016 Aug; 6(8):820-5. PubMed ID: 26992029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of dupilumab versus endoscopic sinus surgery for the treatment of type-2 chronic rhinosinusitis with nasal polyps: a preliminary report.
    Orlando P; Licci G; Kuitche D; Matucci A; Vultaggio A; Gallo O; Maggiore G
    Eur Arch Otorhinolaryngol; 2024 Mar; 281(3):1317-1324. PubMed ID: 37910208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dupilumab as Add-on Therapy for Chronic Rhinosinusitis With Nasal Polyposis in Aspirin Exacerbated Respiratory Disease.
    Mustafa SS; Vadamalai K; Scott B; Ramsey A
    Am J Rhinol Allergy; 2021 May; 35(3):399-407. PubMed ID: 32967430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis comparing dupilumab and aspirin desensitization therapy for chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease.
    Yong M; Wu YQ; Howlett J; Ballreich J; Walgama E; Thamboo A
    Int Forum Allergy Rhinol; 2021 Dec; 11(12):1626-1636. PubMed ID: 34309219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of dupilumab treatment versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps.
    Dharmarajan H; Falade O; Lee SE; Wang EW
    Int Forum Allergy Rhinol; 2022 Aug; 12(8):986-995. PubMed ID: 34919344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dupilumab in chronic rhinosinusitis with nasal polyps: Real life data in a multicentric Sicilian experience.
    Galletti C; Ragusa M; Sireci F; Ciodaro F; Barbieri MA; Giunta G; Grigaliute E; Immordino A; Lorusso F; Dispenza F; Freni F; Galletti F; Gallina S; La Mantia I; Galletti B
    Am J Otolaryngol; 2024; 45(1):104106. PubMed ID: 37948824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials.
    Mullol J; Laidlaw TM; Bachert C; Mannent LP; Canonica GW; Han JK; Maspero JF; Picado C; Daizadeh N; Ortiz B; Li Y; Ruddy M; Laws E; Amin N
    Allergy; 2022 Apr; 77(4):1231-1244. PubMed ID: 34459002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of Life Outcomes in Frontal Sinus Surgery.
    Georgalas C; Detsis M; Geramas I; Terzakis D; Liodakis A
    J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32650386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Dupilumab on Sinonasal Symptoms and Outcomes in Severe Chronic Rhinosinusitis With Nasal Polyps.
    Hopkins C; Mullol J; Khan AH; Lee SE; Wagenmann M; Hellings P; Fokkens W; Msihid J; Nair R; Kamat S; Nash S; Radwan A; Jacob-Nara JA; Deniz Y; Rowe PJ
    Otolaryngol Head Neck Surg; 2024 Apr; 170(4):1173-1182. PubMed ID: 38156522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiological Versus Clinical 1-Year Outcomes of Dupilumab in Refractory CRSwNP: A Real-Life Study.
    Giombi F; Pace GM; Nappi E; Giunta G; Muci G; Pirola F; Ferreli F; Heffler E; Paoletti G; Giannitto C; Mercante G; Francone M; Spriano G; Canonica GW; Malvezzi L
    Laryngoscope; 2024 Jun; 134(6):2626-2633. PubMed ID: 38126613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Appropriate extent of surgery for aspirin-exacerbated respiratory disease.
    Muhonen EG; Goshtasbi K; Papagiannopoulos P; Kuan EC
    World J Otorhinolaryngol Head Neck Surg; 2020 Dec; 6(4):235-240. PubMed ID: 33336179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic Rhinosinusitis Outcomes of Patients With Aspirin-Exacerbated Respiratory Disease Treated With Budesonide Irrigations: A Case Series.
    Talat R; Gengler I; Phillips KM; Caradonna DS; Gray ST; Sedaghat AR
    Ann Otol Rhinol Laryngol; 2022 Oct; 131(10):1130-1136. PubMed ID: 34775833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dupilumab (Dupixent
    Jansen F; Becker B; Eden JK; Breda PC; Hot A; Oqueka T; Betz CS; Hoffmann AS
    Eur Arch Otorhinolaryngol; 2023 Apr; 280(4):1741-1755. PubMed ID: 36242612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
    Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
    Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term morbidity after the endoscopic modified Lothrop (Draf-III) procedure compared with Draf-IIa.
    Jafari A; Tringale KR; Panuganti BA; Acevedo JR; Pang J; DeConde AS
    Am J Rhinol Allergy; 2017 Jul; 31(4):265-270. PubMed ID: 28716178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-reported olfaction improves following outside-in Draf III frontal sinus surgery for chronic rhinosinusitis.
    Wong EH; Do TQ; Harvey RJ; Orgain CA; Sacks R; Kalish L
    Laryngoscope; 2019 Jan; 129(1):25-30. PubMed ID: 30229923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.